BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 34364829)

  • 1. A European Model for an Organised Risk-stratified Early Detection Programme for Prostate Cancer.
    Van Poppel H; Hogenhout R; Albers P; van den Bergh RCN; Barentsz JO; Roobol MJ
    Eur Urol Oncol; 2021 Oct; 4(5):731-739. PubMed ID: 34364829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
    Alberts AR; Roobol MJ; Verbeek JFM; Schoots IG; Chiu PK; Osses DF; Tijsterman JD; Beerlage HP; Mannaerts CK; Schimmöller L; Albers P; Arsov C
    Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implications of the European Association of Urology Recommended Risk Assessment Algorithm for Early Prostate Cancer Detection.
    Israël B; Hannink G; Barentsz JO; van der Leest MMG
    Eur Urol Open Sci; 2022 Sep; 43():1-4. PubMed ID: 35845549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific Antigen Testing as Part of a Risk-Adapted Early Detection Strategy for Prostate Cancer: European Association of Urology Position and Recommendations for 2021.
    Van Poppel H; Roobol MJ; Chapple CR; Catto JWF; N'Dow J; Sønksen J; Stenzl A; Wirth M
    Eur Urol; 2021 Dec; 80(6):703-711. PubMed ID: 34407909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019.
    Gandaglia G; Albers P; Abrahamsson PA; Briganti A; Catto JWF; Chapple CR; Montorsi F; Mottet N; Roobol MJ; Sønksen J; Wirth M; van Poppel H
    Eur Urol; 2019 Aug; 76(2):142-150. PubMed ID: 31092338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of Prostate Cancer Found at Fifth Screening in the European Randomized Study of Screening for Prostate Cancer Rotterdam: Can We Selectively Detect High-grade Prostate Cancer with Upfront Multivariable Risk Stratification and Magnetic Resonance Imaging?
    Alberts AR; Schoots IG; Bokhorst LP; Drost FH; van Leenders GJ; Krestin GP; Dwarkasing RS; Barentsz JO; Schröder FH; Bangma CH; Roobol MJ
    Eur Urol; 2018 Mar; 73(3):343-350. PubMed ID: 28647216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early detection of prostate cancer: European Association of Urology recommendation.
    Heidenreich A; Abrahamsson PA; Artibani W; Catto J; Montorsi F; Van Poppel H; Wirth M; Mottet N;
    Eur Urol; 2013 Sep; 64(3):347-54. PubMed ID: 23856038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prostate cancer screening using a combination of risk-prediction, MRI, and targeted prostate biopsies (STHLM3-MRI): a prospective, population-based, randomised, open-label, non-inferiority trial.
    Nordström T; Discacciati A; Bergman M; Clements M; Aly M; Annerstedt M; Glaessgen A; Carlsson S; Jäderling F; Eklund M; Grönberg H;
    Lancet Oncol; 2021 Sep; 22(9):1240-1249. PubMed ID: 34391509
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Designing and Implementing a Population-based Organised Prostate Cancer Testing Programme.
    Alterbeck M; Järbur E; Thimansson E; Wallström J; Bengtsson J; Björk-Eriksson T; Bjartell A; Bratt O; Jiborn T; Arnsrud Godtman R
    Eur Urol Focus; 2022 Nov; 8(6):1568-1574. PubMed ID: 35811285
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Changing the Prostate Cancer Detection Paradigm: Clinical Application of European Association of Urology Guideline-recommended Magnetic Resonance Imaging-based Risk Stratification in Men with Suspected Prostate Cancer.
    Tully KH; Bahlburg H; Berg S; Hanske J; von Landenberg N; Noldus J; Palisaar RJ; Roghmann F; Brock M
    Eur Urol Focus; 2021 Sep; 7(5):1011-1018. PubMed ID: 33036953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
    Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
    Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
    Mottet N; Bellmunt J; Bolla M; Briers E; Cumberbatch MG; De Santis M; Fossati N; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; Matveev VB; Moldovan PC; van den Bergh RCN; Van den Broeck T; van der Poel HG; van der Kwast TH; Rouvière O; Schoots IG; Wiegel T; Cornford P
    Eur Urol; 2017 Apr; 71(4):618-629. PubMed ID: 27568654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prostate Cancer Risk Assessment in Biopsy-naïve Patients: The Rotterdam Prostate Cancer Risk Calculator in Multiparametric Magnetic Resonance Imaging-Transrectal Ultrasound (TRUS) Fusion Biopsy and Systematic TRUS Biopsy.
    Mannaerts CK; Gayet M; Verbeek JF; Engelbrecht MRW; Savci-Heijink CD; Jager GJ; Gielens MPM; van der Linden H; Beerlage HP; de Reijke TM; Wijkstra H; Roobol MJ
    Eur Urol Oncol; 2018 Jun; 1(2):109-117. PubMed ID: 31100233
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prostate cancer screening-current overview].
    De Vrieze M; Hübner A; Al-Monajjed R; Albers P; Radtke JP; Schimmöller L; Boschheidgen M
    Radiologie (Heidelb); 2024 Jun; 64(6):479-487. PubMed ID: 38743100
    [TBL] [Abstract][Full Text] [Related]  

  • 15. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
    Mottet N; van den Bergh RCN; Briers E; Van den Broeck T; Cumberbatch MG; De Santis M; Fanti S; Fossati N; Gandaglia G; Gillessen S; Grivas N; Grummet J; Henry AM; van der Kwast TH; Lam TB; Lardas M; Liew M; Mason MD; Moris L; Oprea-Lager DE; van der Poel HG; Rouvière O; Schoots IG; Tilki D; Wiegel T; Willemse PM; Cornford P
    Eur Urol; 2021 Feb; 79(2):243-262. PubMed ID: 33172724
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective Validation Study of a Novel Integrated Pathway Based on Clinical Features, Magnetic Resonance Imaging Biomarkers, and MicroRNAs for Early Detection of Prostate Cancer.
    Pecoraro M; Catanzaro G; Conte F; Besharat ZM; Messina E; Laschena L; Trocchianesi S; Splendiani E; Sciarra A; Catalano C; Paci P; Ferretti E; Panebianco V
    Eur Urol Oncol; 2024 Feb; 7(1):73-82. PubMed ID: 37270379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overdiagnosis and overtreatment of prostate cancer.
    Loeb S; Bjurlin MA; Nicholson J; Tammela TL; Penson DF; Carter HB; Carroll P; Etzioni R
    Eur Urol; 2014 Jun; 65(6):1046-55. PubMed ID: 24439788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Personalized strategies in population screening for prostate cancer.
    Remmers S; Roobol MJ
    Int J Cancer; 2020 Dec; 147(11):2977-2987. PubMed ID: 32394421
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.